42 filings
6-K
MOLN
Molecular Partners AG
26 Aug 24
Molecular Partners Reports H1 2024 Corporate Highlights and Financials
4:00pm
6-K
MOLN
Molecular Partners AG
14 Jun 24
Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024
10:44am
6-K
MOLN
Molecular Partners AG
11 Jun 24
Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024
10:16am
6-K
MOLN
Molecular Partners AG
3 Jun 24
Current report (foreign)
5:06pm
6-K/A
MOLN
Molecular Partners AG
17 May 24
Current report (foreign) (amended)
6:25am
6-K
9m94fiv jd
16 May 24
Current report (foreign)
4:00pm
6-K
tav 8fu88pv6n
26 Mar 24
Molecular Partners Publishes Invitation to Annual General Meeting 2024
9:34am
6-K
r1vm8r7yyjcf7ppfao
8 Jan 24
Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference
12:33pm
6-K
pbjdae5n7df
5 Jan 24
Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies
4:00pm
6-K
vz7qd9geqd
11 Dec 23
Current report (foreign)
6:05am
6-K
1bqhw8rbtul d2vt
2 Nov 23
Current report (foreign)
6:01am
6-K
eixk5yz5sb2j
26 Oct 23
Current report (foreign)
4:00pm
6-K
m89j6j8kujhanhy5
24 Aug 23
Molecular Partners Reports H1 2023 Corporate Highlights and Financials
4:02pm
6-K
66iv26fi
12 May 23
Current report (foreign)
6:05am
6-K
1onaguh krhksalbdhrh
11 May 23
Current report (foreign)
4:00pm
6-K
keuqbbmqrftha
13 Mar 23
Molecular Partners Publishes Invitation to Annual General Meeting 2023
9:30am
6-K
jas bfkyy0nqz
9 Mar 23
Molecular Partners Reports Corporate Highlights From Q4 2022 and Key Financials for Full Year 2022
4:00pm
6-K
lgn lgz24m
17 Jan 23
Current report (foreign)
7:00am
6-K
tnop65t9
10 Nov 22
Molecular Partners Presents Positive Interim Safety and Mechanistic Data From Ongoing Phase 1 Trial of MP0317 for Treatment of Solid Tumors
8:00am
6-K
cc7674uvku hyf
27 Oct 22
Current report (foreign)
4:01pm